Northwest Biotherapeutics Inc
OTC:NWBO

Watchlist Manager
Northwest Biotherapeutics Inc Logo
Northwest Biotherapeutics Inc
OTC:NWBO
Watchlist
Price: 0.32 USD 28%
Market Cap: 489.2m USD

Northwest Biotherapeutics Inc
Free Cash Flow

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Northwest Biotherapeutics Inc
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
Northwest Biotherapeutics Inc
OTC:NWBO
Free Cash Flow
-$45.2m
CAGR 3-Years
4%
CAGR 5-Years
-10%
CAGR 10-Years
8%
Abbvie Inc
NYSE:ABBV
Free Cash Flow
$19.7B
CAGR 3-Years
-4%
CAGR 5-Years
5%
CAGR 10-Years
18%
Gilead Sciences Inc
NASDAQ:GILD
Free Cash Flow
$9.7B
CAGR 3-Years
2%
CAGR 5-Years
3%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Free Cash Flow
$13.1B
CAGR 3-Years
13%
CAGR 5-Years
5%
CAGR 10-Years
3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Free Cash Flow
$3.3B
CAGR 3-Years
-4%
CAGR 5-Years
2%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Free Cash Flow
$3.9B
CAGR 3-Years
-2%
CAGR 5-Years
20%
CAGR 10-Years
20%
No Stocks Found

Northwest Biotherapeutics Inc
Glance View

Market Cap
466.8m USD
Industry
Biotechnology

Northwest Biotherapeutics, Inc. is a biotechnology company, which engages in the development of personalized immune therapies for cancer. The company is headquartered in Bethesda, Maryland and currently employs 20 full-time employees. The company went IPO on 2001-12-14. The firm is focused on developing personalized immune therapies for cancer. The company has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The firm's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. The company has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct, is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and included treatment of a diverse range of more than a dozen types of cancers. Its wholly owned subsidiaries include Flaskworks, Aracaris Ltd, Aracaris Capital, Ltd, Northwest Biotherapeutics B.V., and NW Bio GmbH.

NWBO Intrinsic Value
0.03 USD
Overvaluation 90%
Intrinsic Value
Price

See Also

What is Northwest Biotherapeutics Inc's Free Cash Flow?
Free Cash Flow
-45.2m USD

Based on the financial report for Jun 30, 2025, Northwest Biotherapeutics Inc's Free Cash Flow amounts to -45.2m USD.

What is Northwest Biotherapeutics Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 10Y
8%

Over the last year, the Free Cash Flow growth was 26%. The average annual Free Cash Flow growth rates for Northwest Biotherapeutics Inc have been 4% over the past three years , -10% over the past five years , and 8% over the past ten years .

Back to Top